RedHill Biopharma to present Yeliva data at EORTC-NCI-AACR Symposium
RedHill Biopharma announced a poster presentation on Yeliva for multiple myeloma at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The abstract describes data from preclinical studies and a Phase Ib/II study with Yeliva for the treatment of multiple myeloma. The open-label, dose escalation Phase Ib/II study evaluating Yeliva in patients with refractory or relapsed multiple myeloma that were previously treated with proteasome inhibitors and immunomodulatory drugs is ongoing at Duke University Medical Center. Enrollment for the Phase Ib portion of the study has been completed with a total of 11 patients enrolled and treated in three dose cohorts. Results from the Phase Ib portion of the study did not show any dose-limiting toxicities. Additionally, while efficacy was not the primary endpoint of the Phase I study, it was observed that out of 10 evaluable subjects, two subjects had stable disease for over four months and one patient achieved a very good partial response, or VGPR. In addition, results from preclinical studies demonstrated that SK2 is overexpressed in multiple myeloma cell lines and in human multiple myeloma specimens and plays a critical role in myeloma cell growth, proliferation and survival. Additional preclinical studies described in the abstract demonstrated that treatment with Yeliva effectively inhibited myeloma tumor growth in vitro and in vivo in mouse xenograft models. The authors conclude that Yeliva as a single agent or in combination with a B-cell lymphoma 2 inhibitor has the potential for treatment of relapsed/refractory multiple myeloma patients that were previously treated with proteosome inhibitors and immunomodulatory agents. The Phase Ib/II study with Yeliva for multiple myeloma is supported by a $2M grant from the National Cancer Institute, or NCI, Small Business Innovation Research Program, or SBIR, awarded to Apogee Biotechnology in conjunction with Duke University, with additional support provided by RedHill.